文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

老年骨髓纤维化患者异基因造血细胞移植的预后与超额死亡率分析

Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.
PubMed 文献 · Am J Hematol · 2021-07-08

该研究基于EBMT登记组556例≥65岁骨髓纤维化患者,分析异基因造血细胞移植(allo-HCT)的预后,并与西班牙骨髓纤维化登记组176例接受常规药物治疗的中危-2/高危DIPSS患者进行匹配比较超额死亡率。中位随访3.4年,移植后5年生存率40%,非复发死亡率37%,复发率25%。白消安预处理与死亡率降低相关,而受体CMV+/供体CMV-组合和JAK2突变基因型预测死亡率更高。移植患者在随访第一年超额死亡率高于非移植队列,但在第4至第8年相反。

要点

  • ≥65岁骨髓纤维化患者allo-HCT后5年生存率40%,非复发死亡率37%,复发率25%。
  • 白消安预处理与死亡率降低相关(HR 0.7),尽管复发率高于美法仑方案。
  • 移植第一年超额死亡率高于非移植治疗,但第4-8年低于非移植治疗。

核心结论

  • 在≥65岁骨髓纤维化患者中,allo-HCT早期超额死亡率高于常规药物治疗,但长期(第4-8年)超额死亡率低于非移植队列。
  • 白消安预处理与死亡率降低相关,而受体CMV+/供体CMV-组合和JAK2突变基因型预测死亡率更高。

研究设计与样本

  • 研究分析了EBMT登记组中556例年龄≥65岁的骨髓纤维化患者接受allo-HCT的结局。
  • 非移植队列包括西班牙骨髓纤维化登记组中176例中危-2或高危DIPSS患者,接受常规药物治疗。
  • 比较移植与非移植患者的超额死亡率(相对于匹配的一般人群)。

主要发现

  • 中位随访3.4年,移植后估计5年生存率40%,非复发死亡率37%,复发率25%。
  • 白消安预处理与死亡率降低相关(HR: 0.7, 95% CI: 0.5-0.9)。
  • 受体CMV+/供体CMV-组合(HR: 1.7, 95% CI: 1.2-2.4)和JAK2突变基因型(HR: 1.9, 95% CI: 1.1-3.5)预测死亡率更高。
  • 白消安预处理与改善生存相关,因其非复发死亡率较低,尽管与美法仑方案相比复发率较高。
  • 移植患者第一年超额死亡率高于非移植队列(比率: 1.93, 95% CI: 1.13-2.80),而第4至第8年相反(比率: 0.31, 95% CI: 0.18-0.53)。

临床怎么用

  • 对于≥65岁适合移植的骨髓纤维化患者,allo-HCT的获益需权衡早期超额死亡风险与长期生存优势。
  • 白消安预处理可能因降低非复发死亡率而改善生存,但需注意其较高的复发率。
  • 男性患者可能从allo-HCT中获益更多,因其非移植治疗预后更差。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic cell transplantation (allo-HCT) is increasingly used in older myelofibrosis (MF) patients, but its risk/benefit ratio compared to non-transplant approaches has not been evaluated in this population. We analyzed the outcomes of allo-HCT in 556 MF patients aged ≥65 years from the EBMT registry, and determined the excess mortality over the matched general population of MF patients ≥65 years managed with allo-HCT (n = 556) or conventional drug treatment (n = 176). The non-transplant cohort included patients with intermediate-2 or high risk DIPSS from the Spanish Myelofibrosis Registry. After a median follow-up of 3.4 years, the estimated 5-year survival rate, non-relapse mortality (NRM), and relapse incidence after transplantation was 40%, 37%, and 25%, respectively. Busulfan-based conditioning was associated with decreased mortality (HR: 0.7, 95% CI: 0.5-0.9) whereas the recipient CMV+/donor CMV- combination (HR: 1.7, 95% CI: 1.2-2.4) and the JAK2 mutated genotype (HR: 1.9, 95% CI: 1.1-3.5) predicted higher mortality. Busulfan-based conditioning correlated with improved survival due to less NRM, despite its higher relapse rate when compared with melphalan-based regimens. Excess mortality was higher in transplanted patients than in the non-HCT cohort in the first year of follow-up (ratio: 1.93, 95% CI: 1.13-2.80), whereas the opposite occurred between the fourth and eighth follow-up years (ratio: 0.31, 95% CI: 0.18-0.53). Comparing the excess mortality of the two treatments, male patients seemed to benefit more than females from allo-HCT, mainly due to their worse prognosis with non-transplant approaches. These findings could potentially enhance counseling and treatment decision-making in elderly transplant-eligible MF patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Hernández-Boluda JC, Pereira A, Kröger N, et al. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry. Am J Hematol. 2021. PMID: 34152630. doi:10.1002/ajh.26279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。